Share 'Phase III Trial Finds that Anti-interleukin-1 alpha antibody MABp1 Improves Outcomes Significantly over Placebo'

© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+